Ascentage Pharma Files for $200 Million At-The-Market ADS Offering
MT Newswires Live
Jul 20
Ascentage Pharma (HKG:6855) filed a registration statement with the U.S. Securities and Exchange Commission for a proposed at-the-market offering of up to $200 million in American depositary shares, according to a Sunday Hong Kong bourse filing.
Net proceeds will be used to support the commercialization of olverembatinib and lisaftoclax, ongoing clinical trials, working capital, and general corporate purposes.
The proposed offering is subject to Hong Kong Stock Exchange waivers from certain listing rules, and no ADSs will be sold until the waivers are granted.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.